Skip to main content
SpringerLink
Log in

Important Drug Interactions in Dermatology

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Drug interactions can occur at any step from absorption to elimination of a drug, and can induce adverse as well as beneficial effects. Since systemic drugs are increasingly available and important in the treatment of dermatological diseases, a variety of possible interactions between concomitantly administered drugs have to be considered by dermatologists.

The xenobiotic-metabolising enzyme system cytochrome P450 (CYP) is involved in the metabolism of many drugs, regulating their plasma concentrations and activities. Furthermore, the adverse effects of many drugs depend on the basal activity and inducibility of particular CYP isoenzymes in an individual patient. Since drug therapy in dermatological practice is of increasing complexity, and an increasing number of potent systemic drugs have become commonly used therapeutic agents, this review focuses on the following topics with the aim of optimising dermatological drug therapy.

In the first section, all the different types of drug interactions that can occur through pharmacokinetic and pharmacodynamic mechanisms are introduced briefly, and then discussed systematically with special reference to drugs important for dermatologists. Then, the network of drug interactions that may occur from absorption to elimination is presented. The most important drug interactions mediated by CYP isoenzymes are listed. Finally, the importance of pharmacogenetics for the development of new drugs and its potential impact on the optimisation of individual therapy regimens is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI
Fig. 1
Fig. 2
Table VII
Table VIII

Similar content being viewed by others

References

  1. Tatro DS. Drug interactions facts. St Louis: Facts and Comparisons, 1996:7–14

    Google Scholar 

  2. Bickers DR. Antifungal therapy: potential interactions with other classes of drugs. J Am Acad Dermatol 1994; 31: S87–90

    Article  PubMed  CAS  Google Scholar 

  3. Stockley IH. Drug interactions. Oxford: Blackwell Science, 1994: 3–6

    Google Scholar 

  4. Tucker GT. The rational selection of drug interaction studies: implications of recent advances in drug metabolism. Int J Clin Pharmacol Ther Toxicol 1992; 30: 550–3

    PubMed  CAS  Google Scholar 

  5. Van den Bossche H, Koymanns L, Moereels H. P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacol Ther 1995; 67: 79–100

    Article  Google Scholar 

  6. Roos TC, Jugert FK, Merk HF, et al. Retinoid metabolism in the skin. Pharmacol Rev 1998; 50(2): 315–32

    PubMed  CAS  Google Scholar 

  7. Randat JM, Marchbank CR, Dudley MN. Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clin Infect Dis 1992; 14: 272–84

    Article  Google Scholar 

  8. Andersen WK, Feingold DS. Adverse drug interactions clinically important for the dermatologist. Arch Dermatol 1995; 131: 468–73

    Article  PubMed  CAS  Google Scholar 

  9. Hochster H, Dieterich D, Bozette S. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. Ann Intern Med 1990; 113: 111–7

    PubMed  CAS  Google Scholar 

  10. Merk HF, Eichler G. Anaphylaktoide Reaktionen. In: Plewig C, Korting HC, editors. Fortschritte der praktischen dermatologie und Venerologie. Heidelberg: Springer, 1995: 108–15

    Chapter  Google Scholar 

  11. Sugar EF, Sugar AM, Kreger BE. Effect of common beverages on the dissolution of ketoconazole tablets. AIDS 1995; 6: 1221–2

    Article  Google Scholar 

  12. MacKichan JJ. Protein binding drug displacement interactions: fact or fiction. J Clin Pharmacol 1989; 16(2): 65–73

    Article  CAS  Google Scholar 

  13. Park BK, Pirmohamed M, Kitteringham NR. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther 1995; 68; 385–424

    Article  PubMed  CAS  Google Scholar 

  14. Blomley M, Teare EL, deBelder A, et al. Itraconazole and antituberculosis drugs [letter]. Lancet 1990; 336: 1255

    Article  PubMed  CAS  Google Scholar 

  15. Belpaire FM, Bogaert MG. Cytochrome P450: genetic polymorphism and drug interactions. Acta Clin Belg 1996; 51: 254–60

    PubMed  CAS  Google Scholar 

  16. Kalow W. Pharmacogenetics: its biologic roots and the medical challenge. Clin Pharmacol Ther 1993; 54: 235–41

    Article  PubMed  CAS  Google Scholar 

  17. Guengerich FP, Kim DH. In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by narangenin and other flavonoids. Carcinogenesis 1990; 11: 2275–9

    Article  PubMed  CAS  Google Scholar 

  18. Drayton J, Dickinson G, Rinaldi MG. Coadministration of rifampicin and itraconazole leads to undetectable levels of serum itraconazole [letter]. Clin Infect Dis 1994; 18: 266

    Article  PubMed  CAS  Google Scholar 

  19. Honig P, Baraniuk JN. Adverse effects of H1-receptor antagonists in the cardiovascular system. In: Estelle F, Simons R, editors. Histamine and Hl-receptor antagonists in allergic disease. New York: Marcel Dekker, 1996: 383–412

    Google Scholar 

  20. Meltzer EO, Welch MJ. Adverse effects of Hl-receptor antagonists in the central nerve system. In: Estelle F, Simons R, editors. Histamine and H1-receptor antagonists in allergic disease. New York: Marcel Dekker, 1996: 357–81

    Google Scholar 

  21. Woosley RL, Chen Y, Freiman P. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532–6

    Article  PubMed  CAS  Google Scholar 

  22. Estelle F, Simons R, editors. Histamine and H1-receptor antagonists in allergic disease. New York: Marcel Dekker, 1996

    Google Scholar 

  23. Baciewicz AM, Baciewicz Jr FA. Cyclosporine pharmacokinetic drug interactions. Am J Surg 1989; 157: 264–71

    Article  PubMed  CAS  Google Scholar 

  24. Periti P, Mazzei T, Mini E. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992; 23: 106–31

    Article  PubMed  CAS  Google Scholar 

  25. Shenfield GM, Griffin JM. Clinical pharmacokinetics of contraceptive steroids. An update. Clin Pharmacokinet 1991; 20: 15–37

    Article  CAS  Google Scholar 

  26. Okino K, Weibert RT. Warfarin-griseofulvin interaction. Drug Intell Clin Pharm 1986; 20: 291–93

    PubMed  CAS  Google Scholar 

  27. Patsalos PN, Duncan JS. Antiepileptic drugs: a review of clinically significant drug interactions. Drug Saf 1993; 125: 269–70

    Google Scholar 

  28. Stafstrom CE, Nohria V, Loganbill H. Erythromycin-induced carbamazepine toxicity: a continuing problem. Arch Pediatr Adolesc Med 1995; 149: 99–101

    Article  PubMed  CAS  Google Scholar 

  29. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991;91: 40S–45S

    Article  PubMed  CAS  Google Scholar 

  30. Cameron W, Sun E, Markowith M. Combination use of ritonavir and saquinavir in HIV-infected patients: preliminary safety and activity data [abstract Th.B.934]. In: Program and abstracts of the 11th International Conference on AIDS: 1996 Jul 7–12; Vancouver

  31. Chiba M, Hensleigh M, Lin JH. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Biochem Pharmacol 1997; 53: 1187–95

    Article  PubMed  CAS  Google Scholar 

  32. Cox SR, Ferry JJ, Batts DH, et al. Delavirdine and marketed protease inhibitors: pharmacokinetic interaction studies in healthy volunteers [abstract A372]. In: Program and Abstracts of the IVth Conference on retroviruses and opportunistic infections: 1997 Jan 22–26; Washington

  33. Havlir D, Cheeseman SH, McLaughlin M, et al. High dose nevirapine: safety, pharmacokinetics and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171: 537–45

    Article  PubMed  CAS  Google Scholar 

  34. Murpy R, Gagnier P, Lamson M, et al. Effect of nevirapine on pharmacokinetics of indinavir and ritonavir in HIV-patients [abstract A374]. In: Program and Abstracts of the IVth Conference on retroviruses and opportunistic infections: 1997 Jan 22–26; Washington

  35. Fiske WD, Mayers D, Wagner K, et al. Pharmacokinetics of DMP266 and indinavir multiple oral doses in HIV-infected individuals. In: Program and Abstracts of the IV Conference on Retroviruses and Opportunistic infections: 1997 Jan 22–26; Washingtonn, A568

  36. Merk HF, Bickers DR. Dematopharmakologie und Dermato-therapie. Berlin: Blackwell, 1995: 158–61

    Google Scholar 

  37. Larsen FG, Jakobsen P, Knudsen J, et al. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 1993; 100: 623–7

    Article  PubMed  CAS  Google Scholar 

  38. Larsen FG, Nielsen-Kudsk F, Jakobsen P, et al. Interaction of etretinate with methotrexate pharmacokinetics in psoriatic patients. J Clin Pharmacol 1990; 30: 802–7

    PubMed  CAS  Google Scholar 

  39. Antoniskis D, Larsen RA. Acute progressive renal failure with the simultaneous use of amphotericin B and pentamidine. Antimicrob Agents Chemother 1990; 34: 470–2

    Article  PubMed  CAS  Google Scholar 

  40. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330: 263–72

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by a grant from the German Research Community (Deutsche Forschungsgemeinschaft) (RO12-3/1-1).

Author information

Authors and Affiliations

  1. Department of Dermatology, University Hospital of the University Hospital of the Rheinisch-Westfalische Technische Hochschule Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany

    Thomas Christian Roos &  Hans Friedrich Merk

Authors
  1. Thomas Christian Roos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans Friedrich Merk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans Friedrich Merk.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roos, T.C., Merk, H.F. Important Drug Interactions in Dermatology. Drugs 59, 181–192 (2000). https://doi.org/10.2165/00003495-200059020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200059020-00003

Keywords

Search

Navigation